lisocabtagene maraleucel
bms
['lymsm', 'lymphoma', 'liso-cel', 'dlbcl']
cpi in post-car-t dlbcl benefit seen in patients w pbmcl, otherwise largely ineffective
relapses move fast
just 5% of patients w durable responses to cpi
17% of pts alive mostly received addit subsequent therapies
#ash22 #lymsm #tcellrx 
haematology registrar | fellow @PORTAL_research @harvardmed |
evidence-based medicine | health policy | lymphoma | myeloma |
Fulbright scholar | muso | writer